Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate

Prostate Adenocarcinoma Clinical Trial

— PORT-MAP  

Official title:

Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate (PORT-MAP)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05607342
• Other study ID #: STUDY00148767
• Status: Terminated
• Phase: Early Phase 1
• Start date: January 3, 2023
• Est. completion date: November 6, 2023

Study information

• Verified date: February 2024
• Source: University of Kansas Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the effect of Osanetant on testosterone levels in men with prostate cancer within 28 days of therapy.

Description:

Primary:

To evaluate the effect of Osanetant on testosterone levels in men with prostate cancer within 28 days of therapy.

Secondary:

• To evaluate the effect Osanetant on pituitary hormones (LH/FSH) and estrogen within 28 days of therapy.

• To evaluate the effect of Osanetant on PSA levels after 28 days (approximately 4 weeks) of therapy.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: November 6, 2023
• Est. primary completion date: September 22, 2023
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent

• Males = 18 years

• Histologic diagnosis of adenocarcinoma of the prostate (PCa)

• Planned radical prostatectomy within the study period

• Testosterone >150ng/ml

• Adequate organ function, defined as follows: Result Date

• Leukocytes >1.5K/UL

• Absolute Neutrophil Count >1.5K/UL

• NOTE: Patients with established diagnosis of benign neutropenia are eligible to participate with ANC between 1000-1500 if in the opinion of treating physician the trial treatment does not pose excessive risk of infection to the patient.

• Platelets >100K/UL

• Hemoglobin = 9 g/dL

• Serum creatinine = 1.5 x upper limit of normal (ULN) or calculated creatinine clearance = 50 mL/min using the Cockcroft-Gault equation

• Total bilirubin = 1.5 x ULN OR direct bilirubin = 1 x ULN

• Aspartate aminotransferase and alanine aminotransferase = 2.5 x ULN unless liver metastases are present, in which case they must be = 5 x ULN

• Men with partners of child-bearing potential must agree to practice sexual abstinence or to use the forms of contraception listed in Child-Bearing Potential/Pregnancy section for the duration of study participation. Men of child-bearing potential must not father a child or donate sperm while receiving investigational treatment. Following treatment (standard of care prostatectomy) there is no further child-bearing potential.

Exclusion Criteria:

• Current or recent (within 6 months) use of testosterone/estrogen modulating agents (leuprolide, degarelix, bicalutamide, enzalutamide, apalutamide, darolutamide, abiraterone, systemic ketoconazole, tamoxifen, etc)

• Current use of CYP3A4 inhibitors

• Subjects using the following medications within 2 weeks prior to first dosing (or within 5 times the half-life of that medication, whichever is longer) will be excluded from the study:

• Inhibitors of CYP3A4 (including but not limited to macrolide antibiotics, HIV protease inhibitor, azole antifungal drugs, cyclosporine, calcium channel inhibitor, cimetidine)

• Inducers of CYP3A4 (including but not limited to rifampicin, carbamazepine, efavirenz, bosentan, modafinil, St. John's Wort), Medications with narrow therapeutic index that are metabolized CYP3A4 and/or CYP2D6 are not allowed from screening until up to 5 half-lives after last dose of Osanetant is administered.

• Cognitive impairment (defined as the presence of diagnosed dementia)

• Impaired renal function: Cr >1.8

• Medical history of osteoporosis

• Current systemic corticosteroid, long-term opioid, spironolactone, or eplerenone use

• Has a known allergic reaction to any excipient contained in the study drug formulation

• Active Grade 3 (per the NCI CTCAE, Version 5.0) or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study treatment.

• Active COVID-19 infection

• Any history of underlying liver disorder, including hepatitis (see below)

• Any evidence of acute or chronic hepatitis B or C on screening testing

• Elevation of any or all liver enzymes (ALT, AST, total bilirubin) above the upper limit of normal (ULN) at baseline testing prior to enrollment

• A family history of hepatitis or currently living with a person who has been given a diagnosis of hepatitis

• A history of or currently working as a sex worker

• A history of or currently using intravenous (IV) drugs

• A self-reported history of alcoholic dependency or abuse

• A history of or current diagnosis of cardiovascular disease including heart failure, coronary artery disease, uncontrolled hypertension, uncontrolled diabetes; arrhythmias (or history of), or clinically relevant ECG abnormalities at baseline

Related Conditions & MeSH terms

• Adenocarcinoma
• Prostate Adenocarcinoma

Intervention

Drug:
• Osanetant
To evaluate the effect of Osanetant on the testosterone levels.

Locations

Country	Name	City	State
United States	The University of Kansas Cancer Center, Westwood Campus	Kansas City	Kansas

Sponsors (1)

Lead Sponsor	Collaborator
University of Kansas Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the effect of Osanetant on the testosterone levels.	We will test the ability of Osanetant to suppress testosterone production. A single arm pilot study of Osanetant at 200mg twice daily will be performed. Testosterone levels at baseline will be compared to levels at day 2, 3, 7 ,14, and 28 days of therapy. The overall effect of Osanetant on testosterone levels and the proportion of men achieving castrate levels of testosterone (<50ng/ml) will be assessed. Additionally, the reversibility of this effect will be assessed by evaluating the testosterone levels at 6-8 weeks posttreatment.	28 days
Secondary	To evaluate the effect of Osanetant on LH levels.	Levels of luteinizing hormone (LH) will be measured at baseline and days 2, 3, 7 ,14, and 28. These will be compared at each time point in order to assess the impact of NK3RA on these hormonal parameters.	28 days
Secondary	To evaluate the effect of Osanetant on FSH levels.	Levels of follicle stimulating hormone (FSH) will be measured at baseline and days 2, 3, 7 ,14, and 28. These will be compared at each time point in order to assess the impact of NK3RA on these hormonal parameters.	28 days
Secondary	To evaluate the effect of Osanetant on estradiol levels	Levels of estradiol will be measured at baseline and days 2, 3, 7 ,14, and 28. These will be compared at each time point in order to assess the impact of NK3RA on these hormonal parameters.	28 days
Secondary	To evaluate the effect of Osanetant on PSA levels.	PSA will be compared at baseline and 28 days of therapy in order to evaluate the end biochemical efficacy of Osanetant on men with prostate cancer undergoing curative intent therapy.	28 days